Ionis Pharmaceuticals traded at $44.42 this Wednesday September 28th, increasing $2.15 or 5.09 percent since the previous trading session. Looking back, over the last four weeks, Ionis Pharmaceuticals gained 5.76 percent. Over the last 12 months, its price rose by 32.28 percent. Looking ahead, we forecast Ionis Pharmaceuticals to be priced at 41.94 by the end of this quarter and at 38.30 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Astellas Pharma 1,905.00 28.50 1.52% 3.39%
Agios Pharmaceuticals 29.38 0.66 2.30% -36.42%
Alnylam Pharmaceuticals 210.76 8.15 4.02% 18.77%
Arrowhead Research 33.96 2.76 8.85% -43.99%
BioCryst Pharmaceuticals 12.91 0.39 3.12% -10.22%
Bluebird Bio 5.77 0.32 5.87% -69.60%
BioMarin Pharmaceutical 85.84 2.40 2.88% 11.79%
Esperion Therapeutics 7.31 0.28 3.98% -41.24%
Exelixis 16.19 0.29 1.82% -21.52%
Halozyme Therapeutics 40.25 1.61 4.17% 1.51%
Intercept Pharmaceuticals 17.03 0.36 2.16% 12.26%
Moderna Inc 122.15 -0.08 -0.07% -67.76%
Mirati Therapeutics 70.51 2.95 4.37% -59.53%
Neurocrine Biosciences 102.83 1.47 1.45% 8.94%
Nektar Therapeutics 3.21 0.16 5.25% -82.10%
Novartis 74.82 0.43 0.58% -3.12%
Omeros 3.47 0.15 4.52% -74.10%
Pfizer 44.43 0.34 0.77% 2.07%
PTC Therapeutics 51.18 1.78 3.60% 38.14%
Ultragenyx Pharmaceutical 41.27 0.98 2.43% -52.08%
Regeneron Pharmaceuticals 705.42 10.41 1.50% 16.56%
Roche Holding 325.45 12.85 4.11% -3.73%
Sarepta Therapeutics 109.91 1.58 1.46% 23.81%
Vertex Pharmaceuticals 292.41 7.67 2.69% 61.21%


Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on two core franchises: neurology and cardiometabolic. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. Its products in pipeline include tofersen for SOD1-ALS, eplontersen (IONIS-TTR-LRX) for TTR, IONIS-APOCIII-LRx for familial chylomicronemia syndrome (FCS), pelacarsen for lipoprotein(a) (Lp), driven cardiovascular disease and ION363 for amyotrophic lateral sclerosis (ALS), with mutations in the fused in sarcoma gene (FUS).